NCT06923111 - PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS] | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2029

Conditions

Sickle Cell Disease

Interventions

DRUG

Xromi

Xromi is indicated for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 9 months of age as part of standard clinical practice

Trial Locations (5)

SS16 5NL

NOT_YET_RECRUITING

Basildon University Hospital, Basildon

CF14 4XW

NOT_YET_RECRUITING

Noah's Ark Children's Hospital for Wales, Cardiff

NW1 2PG

RECRUITING

University College London Hospital, London

E1 1FR

NOT_YET_RECRUITING

The Royal London Hospital, London

SE5 9RS

RECRUITING

Kings College Hospital, London